Home›Ziftomenib

Ziftomenib

Also known as: Komzifti

Menin InhibitorMenin Inhibitors

Route: Oral

5 interactions on record⛔ Black Box Warning

Ziftomenib has 5 known drug interactions based on U.S. FDA drug labeling data. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anakinra, Antacids Containing Calcium, Cyp3a Inducers. Patients taking Ziftomenib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Major: 5

Major (5)

Ziftomenib + Anakinra— Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.
Ziftomenib + Antacids Containing Calcium— Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.
Ziftomenib + Cyp3a Inducers— Avoid concomitant use. May decrease ziftomenib exposure and reduce efficacy of KOMZIFTI.
Ziftomenib + Drugs That Prolong The Qt Interval— Avoid concomitant use. If unavoidable, obtain ECGs and monitor for QTc prolongation. Ziftomenib causes QTc prolongation;…
Ziftomenib + Mao Inhibitors— Avoid concomitant use. Decreases ziftomenib exposure and may reduce efficacy of KOMZIFTI.

Ziftomenib + Anakinra⚠️Major

Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.

Ziftomenib + Antacids Containing Calcium⚠️Major

Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.

Ziftomenib + Cyp3a Inducers⚠️Major

Avoid concomitant use. May decrease ziftomenib exposure and reduce efficacy of KOMZIFTI.

Ziftomenib + Drugs That Prolong The Qt Interval⚠️Major

Avoid concomitant use. If unavoidable, obtain ECGs and monitor for QTc prolongation. Ziftomenib causes QTc prolongation; concomitant use may result in serious arrhythmias and sudden death.

Ziftomenib + Mao Inhibitors⚠️Major

Avoid concomitant use. Decreases ziftomenib exposure and may reduce efficacy of KOMZIFTI.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.